Quince Therapeutics retracts false claim about IntraBio's Phase 2 study for NALL in A-T

Quince Therapeutics, Inc.

Quince stated on Oct 2 Investor Day that IntraBio's NALL Phase 2 failed all endpoints in A-T; now retracts that statement.
The statement was based on a different study (EJPN Article), not the IntraBio Phase 2 study; Quince removed it from materials.
The EJPN Article found NALL failed to improve motor function significantly but improved some symptoms (e.g., nausea, constipation).
Quince advises investors not to rely on the retracted statement; underlying facts did not support the original claim.

item 7.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.